Canada markets closed
  • S&P/TSX

    18,881.19
    +436.97 (+2.37%)
     
  • S&P 500

    3,678.43
    +92.81 (+2.59%)
     
  • DOW

    29,490.89
    +765.38 (+2.66%)
     
  • CAD/USD

    0.7344
    +0.0002 (+0.02%)
     
  • CRUDE OIL

    83.71
    +0.08 (+0.10%)
     
  • BTC-CAD

    26,670.13
    +410.37 (+1.56%)
     
  • CMC Crypto 200

    445.37
    +10.01 (+2.30%)
     
  • GOLD FUTURES

    1,705.30
    +3.30 (+0.19%)
     
  • RUSSELL 2000

    1,708.87
    +44.15 (+2.65%)
     
  • 10-Yr Bond

    3.6510
    -0.1530 (-4.02%)
     
  • NASDAQ futures

    11,373.00
    +87.25 (+0.77%)
     
  • VOLATILITY

    30.10
    -1.52 (-4.81%)
     
  • FTSE

    6,908.76
    +14.95 (+0.22%)
     
  • NIKKEI 225

    26,840.75
    +624.96 (+2.38%)
     
  • CAD/EUR

    0.7463
    -0.0005 (-0.07%)
     

Cipher Pharmaceuticals Schedules Q2 2022 Earnings Release and Conference Call

·1 min read

MISSISSAUGA, ON, Aug. 5, 2022 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q2 2022 financial results on Thursday, August 11, 2022 after market close. The Company will also host a conference call on Friday, August 12, 2022 at 8:30am ET to discuss the results and corporate developments.

CONFERENCE CALL DETAILS

DATE:

August 12, 2022



TIME:

8:30 a.m. ET



DIAL-IN NUMBER:

(647) 484-0475 or (888) 220-8451



CONFERENCE ID:

7538758



REPLAY DIAL-IN:

(888) 203-1112 (playback 7538758#)


Expires August 19, 2022



WEBCAST:   

https://app.webinar.net/871ZpObNzYX

 

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. For more information, visit www.cipherpharma.com.

SOURCE Cipher Pharmaceuticals Inc.

Cision
Cision

View original content: http://www.newswire.ca/en/releases/archive/August2022/05/c3281.html